Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-04-06
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsightVERA — Vera Therapeutics, Inc
NASDAQ · Biotechnology · Biotechnology
$40.06-9.65%Market cap2.85B
- Latest Close
- $40.06
- 30-Day Move
- -9.7%
- Market Cap
- $2.9B
- Shares Outstanding
- 71,360,000
- P/B Ratio
- 5.87
- ROE
- -49.6%
NASDAQ:VERABiotechnology / BiotechnologyDelayed public snapshot
Vera Therapeutics, Inc
A read-only Alphactor snapshot forVera Therapeutics, Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$40.06
30-Day Move
-9.7%
Market Cap
$2.9B
Shares Outstanding
71,360,000
P/B Ratio
5.87
ROE
-49.6%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$40.06
-9.7%last 90 delayed daily bars
Market cap$2.9B
90D High
$56.05
90D Low
$37.51
Avg Volume
1,213,271
What stands out
VERA is down 9.7% over the last 30 trading days shown on this page.
Latest operating income is $-94M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Dark Pool Short %
59.5%
Fundamentals snapshot
Latest Close
$40.06
30-Day Move
-9.7%
Market Cap
$2.9B
Shares Outstanding
71,360,000
P/B Ratio
5.87
ROE
-49.6%
ROA
-40.8%
Debt / Equity
0.12
Current Ratio
13.64
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-94M
Net Income
$-91M
Gross Margin
--
Net Margin
--
Current Ratio
13.64
Debt / Equity
0.12
Quality snapshot
Altman Z
11.38
Safe
Piotroski
1
Weak (0-3)
Cash Conversion
0.80x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-91M | $-89M | $-68M |
| 2023-12-31 | $0 | $-102M | $-96M | $-92M |
| 2024-12-31 | $0 | $-167M | $-152M | $-136M |
| 2025-12-31 | $0 | $-315M | $-300M | $-242M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Publisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico', homepage_url='https://www.fool.com/', logo_url='https://s3.massive.com/public/assets/news/logos/themotleyfool.svg', name='The Motley Fool')•2026-03-13
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA DecisionPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2026-03-05
Vera Therapeutics Appoints Christopher Hite to Board of DirectorsPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-12-10
Vera Therapeutics Announces Pricing of Public Offering of Class A Common StockPublisher(favicon_url='https://s3.massive.com/public/assets/news/favicons/globenewswire.ico', homepage_url='https://www.globenewswire.com', logo_url='https://s3.massive.com/public/assets/news/logos/globenewswire.svg', name='GlobeNewswire Inc.')•2025-11-21
BK Virus Infection Market Trends, Strategies and Business Prospects 2025-2035 - Lack of FDA-Approved Drugs Spurs Innovation in BK Virus TreatmentAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2,000,830 | 0.03% | 2026-03-31 |
| T. Rowe Price Health Sciences Fund, Inc. | 1,968,700 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1,878,847 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 1,351,594 | 0.02% | 2026-02-28 |
| T. Rowe Price New Horizons Fund, Inc. | 1,135,135 | 0.02% | 2025-12-31 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 872,624 | 0.01% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 696,200 | 0.01% | 2025-12-31 |
| T. ROWE PRICE QUANTITATIVE Mgmt Fd.S, INC.-T. Rowe Price Integrated U. | 681,881 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
T. Rowe Price
Filed 2025-08-14
--
--
Vanguard Group
Filed 2026-01-29
$181M
+11.9%
FMR LLC (Fidelity)
Filed 2026-02-17
$146M
+1.5%
BlackRock
Filed 2024-05-10
$143M
--
Geode Capital Management
Filed 2026-02-09
$73M
+9.3%
Goldman Sachs
Filed 2026-02-10
$57M
+47.7%
Citadel Advisors
Filed 2025-11-14
$47M
--
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.